IBRX - ImmunityBio LadRx end licensing deal for cancer drug
2024-06-04 07:06:40 ET
More on ImmunityBio, LadRx, etc.
- ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains
- ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications
- ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle
- ImmunityBio immunotherapy shows positive overall survival in lung cancer trial
- Day One wins FDA nod for brain cancer therapy, Ojemda